Active Not Recruiting INTERVENTIONAL NCT06628362

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Sponsor: Carmot Therapeutics, Inc.

Conditions Overweight or Obese Type 2 Diabetes Mellitus (T2DM)

Interventions Enicepatide Placebo

Updated 14 times since 2024 Last updated: Apr 14, 2026 Started: Nov 21, 2024 Primary completion: Jun 1, 2026 Completion: Sep 24, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Overweight or Obese and Type 2 Diabetes Mellitus (T2DM) and is currently ongoing. Carmot Therapeutics, Inc. leads this study, which shows 14 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

14 versions recorded

Apr 18, 2026 — Present [daily]

Active Not Recruiting

Phase: PHASE2 → None
Feb 2026 — Apr 2026 [monthly]

Active Not Recruiting PHASE2
Nov 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2

▶ Show 9 earlier versions

Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE2
May 2025 — Jul 2025 [monthly]

Recruiting PHASE2
Apr 2025 — May 2025 [monthly]

Recruiting PHASE2
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE2
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE2
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

Contact Information

Sponsor contact:

Carmot Therapeutics, Inc.
Hoffmann-La Roche

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ames, United States , Auckland, New Zealand , Austin, United States , Birmingham, United States , Birmingham, United States , Boca Raton, United States , Bowie, United States , Brampton, Canada , Brampton, Canada , Brooklyn, United States and 60 more locations